Last $674.48 MXN
Change Today +14.48 / 2.19%
Volume 105.0K
As of 4:08 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

sanofi-adr (SNYN) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/25/14 - $746.00
52 Week Low
11/4/14 - $615.18
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SANOFI-ADR (SNYN)

sanofi-adr (SNYN) Details

Sanofi discovers, develops, and distributes therapeutic solutions. Its primary products include Lantus and Apidra analogs of human insulin; Insuman insulin solutions and suspensions; Amaryl, a sulfonylurea; Lyxumia, a prandial GLP-1 receptor agonist; BGStar, iBGStar, and MyStar Extra blood glucose meters; Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme for mucopolysaccharidosis Type I; Aubagio for multiple sclerosis; and Lemtrada, a humanized monoclonal antibody. The company’s products also comprise Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; Jevtana for prostate cancer; Thymoglobulin, an immuno-suppressive and immuno-modulating agent; Mozobil stem cell mobilizer; and Zaltrap recombinant fusion protein. In addition, it offers thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. Further, it provides Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements for pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has a strategic alliance with Illumina, Inc. to develop a next-generation sequencing based oncology test system. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

112,128 Employees
Last Reported Date: 03/7/14
Founded in 1973

sanofi-adr (SNYN) Top Compensated Officers

Chairman, Interim Chief Executive Officer, Ch...
Total Annual Compensation: €700.0K
Compensation as of Fiscal Year 2013.

sanofi-adr (SNYN) Key Developments

Sanofi to Invest EUR 35 Million to Upgrade Production in Italy

Sanofi will invest EUR 34.7 million in the development of Italian businesses under a contract signed with Invitalia. Invitalia will allocate further EUR 4.3 million to the project. Sanofi will use most of the funds to upgrade its production facility in Scoppito, southern Italy. The company will buy new technologies and equipment to provide more production capacity and transfer production from other plants. Invitalia said funds will also be invested in a development programme envisaging introduction of experimental process and product innovations. The plant's upgrading is scheduled to be completed by June 2016.

Sanofi Announces Opening of Production Facility in King Abdullah Economic City

Sanofi announced the opening of its production facility in King Abdullah Economic City's (KAEC) Industrial Valley. The opening of a manufacturing facility was therefore a natural next step and KAEC was chosen as the perfect location due to the pro-business and competitive environment of the region. The new factory is creating jobs for Saudi citizens and transfers Sanofi technology for the benefit of the Kingdom and the Gulf Cooperation Council (GCC).

Sanofi Mulls Acquisitions

Sanofi (ENXTPA:SAN) is seeking acquisitions. Sanofi is looking to diversify beyond drug development, according to Reuters, and it may do so through acquisitions. Serge Weinberg, interim Chief Executive Officer of Sanofi said, "We want to have businesses like consumer healthcare, veterinary medicine and vaccines that are less strongly driven by innovation but grow continuously and are more stable." Weinberg went onto say that the company would be prepared and able to make acquisitions in those areas if the right opportunity presented itself.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNYN:MM $674.48 MXN +14.48

SNYN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $67.71 USD -0.21
Amgen Inc $170.17 USD +1.69
Bayer AG €115.80 EUR +1.79
Bristol-Myers Squibb Co $61.30 USD +0.51
Celgene Corp $117.18 USD +0.70
View Industry Companies

Industry Analysis


Industry Average

Valuation SNYN Industry Range
Price/Earnings 23.7x
Price/Sales 2.9x
Price/Book 1.9x
Price/Cash Flow 14.5x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANOFI-ADR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at